Results 31 to 40 of about 36,160 (268)
Brazilian Journal of Infectious Diseases, 2016 Invasive pneumococcal disease is a relevant public health problem in Brazil, especially among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine was introduced to the immunization schedule of Brazilian children under two ...
Carolina Regis Leite +5 more
doaj +1 more source
Changes in the Features of Invasive Pneumococcal Disease after Introduction of the Seven-valent Pneumococcal Conjugate Vaccine in a Regional Core Hospital of Kochi, Japan [PDF]
, 2015 Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2007, invasive pneumococcal disease has declined, but the incidence of Streptococcus pneumoniae serotype 19A has risen worldwide.
Akane Kanazawa +10 more
core +1 more source
Human Vaccines & Immunotherapeutics, 2012 HIV-patients have excess of pneumococcal infection. We immunized 40 HIV-patients twice with pneumococcal conjugate vaccine (Prevnar, Pfizer) +/− a TLR9 agonist (CPG 7909).
Rasmus Offersen +5 more
doaj +1 more source
Predicting optimal impact interventions in the post‐HPV vaccination world
International Journal of Cancer, EarlyView.Abstract Prophylactic vaccination is a powerful tool that changes exposure to infections and associated morbidity of preventable diseases. We discuss the impact of pneumococci and human papillomavirus (HPV) vaccination on the population biology of the two micro‐organisms and related public health effects.
Matti Lehtinen +7 more
wiley +1 more source
The Political Economy of Patent Buyouts
The RAND Journal of Economics, EarlyView.ABSTRACT Incentivizing innovation through buyouts may alleviate the social costs associated with patent power, but the political economy and feasibility of this potentially important financing mechanism have been understudied. We study an international setting of countries with different innovation and financing capabilities, and where financing ...
Amal Ahmad +2 more
wiley +1 more source
Биопрепараты: Профилактика, диагностика, лечение, 2022 Diseases caused by Streptococcus pneumoniae, as well as antibiotic resistance of its serotypes, are the leading cause of death amongst children worldwide.
V. P. Trukhin +5 more
doaj +1 more source
Personalized Cancer Vaccines in the Clinical Trial Pipeline
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley +1 more source
BMC Infectious Diseases, 2019 Background There is great interest in the use of reduced dosing schedules for pneumococcal conjugate vaccines, a strategy premised on maintaining an acceptable level of protection against disease and carriage of the organism.
Alan Yang, Francisco Cai, Marc Lipsitch
doaj +1 more source
Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: A longitudinal household study [PDF]
, 2005 Background. Natural immunity to Streptococcus pneumoniae is thought to be induced by exposure to S. pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S.
Andrews, N +12 more
core
Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine. [PDF]
, 2018 Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Although this is a vaccine preventable disease, S. pneumoniae still causes over 1 million deaths per year, mainly in children under the age of five.
Abouelhadid, Sherif +7 more
core +3 more sources